Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.
Mandalà M, Lorigan P, Sergi MC, Benannoune N, Serra P, Vitale MG, Giannarelli D, Arance AM, Couselo EM, Neyns B, Tucci M, Guida M, Spagnolo F, Rossi E, Occelli M, Queirolo P, Quaglino P, Depenni R, Merelli B, Placzke J, Di Giacomo AM, Del Vecchio M, Indini A, da Silva IP, Menzies AM, Long GV, Robert C, Rutkowski P, Ascierto PA. Mandalà M, et al. Among authors: merelli b. Eur J Cancer. 2024 Mar;199:113542. doi: 10.1016/j.ejca.2024.113542. Epub 2024 Jan 19. Eur J Cancer. 2024. PMID: 38266540 Free article.
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
Rubatto M, Fava P, Stanganelli I, Ribero S, Pigozzo J, Di Giacomo AM, Ridolfi L, Tronconi MC, Trojaniello C, Bersanelli M, Garutti M, Indini A, De Risi I, De Tursi M, Merelli B, Morgese F, Occelli M, Cappellini GCA, Poletto S, Fedele D, Brugnara S, Frisinghelli M, Formisano L, Conca R, Tucci M, Russillo M, Ceroni L, Queirolo P, Targato G, Strippoli S, Mandalà M, Guida M, Quaglino P. Rubatto M, et al. Among authors: merelli b. Eur J Cancer. 2023 Jul;187:25-35. doi: 10.1016/j.ejca.2023.03.020. Epub 2023 Mar 23. Eur J Cancer. 2023. PMID: 37099946
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.
Ascierto PA, Di Giacomo AM, Chiarion Sileni V, Queirolo P, Spagnolo F, De Galitiis F, Cognetti F, Mandalà M, Guidoboni M, Rinaldi G, Depenni R, Consoli F, Troiani T, Guida M, Marconcini R, Ferrucci PF, Strippoli S, Fava P, Merelli B, Simeone E, Di Guardo L, Giannarelli D, Maio M, Quaglino P, Del Vecchio M. Ascierto PA, et al. Among authors: merelli b. Eur J Cancer. 2023 Sep;191:113246. doi: 10.1016/j.ejca.2023.113246. Epub 2023 Jul 19. Eur J Cancer. 2023. PMID: 37549531
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab.
Queirolo P, Dozin B, Morabito A, Banelli B, Carosio R, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Ascierto PA, Madonna G, Simeone E, De Galitiis F, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Ghilardi L, Merelli B, Fava P, Osella-Abate S, Guidoboni M, Romani M, Ferone D, Spagnolo F, Pistillo MP; Italian Melanoma Intergroup (IMI). Queirolo P, et al. Among authors: merelli b. Eur J Cancer. 2018 Jul;97:59-61. doi: 10.1016/j.ejca.2018.04.005. Epub 2018 May 7. Eur J Cancer. 2018. PMID: 29743138 No abstract available.
Health-related quality of life in patients with fully resected BRAFV600 mutation-positive melanoma receiving adjuvant vemurafenib.
Schadendorf D, Di Giacomo AM, Demidov L, Merelli B, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Hong A, Lewis K; BRIM8 Investigators. Schadendorf D, et al. Among authors: merelli b. Eur J Cancer. 2019 Dec;123:155-161. doi: 10.1016/j.ejca.2019.09.019. Epub 2019 Nov 5. Eur J Cancer. 2019. PMID: 31704549 Free article. Clinical Trial.
The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors.
Massi D, Rulli E, Cossa M, Valeri B, Rodolfo M, Merelli B, De Logu F, Nassini R, Del Vecchio M, Di Guardo L, De Penni R, Guida M, Sileni VC, Di Giacomo AM, Tucci M, Occelli M, Portelli F, Vallacchi V, Consoli F, Quaglino P, Queirolo P, Baroni G, Carnevale-Schianca F, Cattaneo L, Minisini A, Palmieri G, Rivoltini L, Mandalà M; Italian Melanoma Intergroup. Massi D, et al. Among authors: merelli b. J Immunother Cancer. 2019 Nov 15;7(1):308. doi: 10.1186/s40425-019-0797-4. J Immunother Cancer. 2019. PMID: 31730502 Free PMC article.
Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI).
Mandalà M, Galli F, Patuzzo R, Maurichi A, Mocellin S, Rossi CR, Rulli E, Montesco M, Quaglino P, Caliendo V, De Giorgi V, Merelli B, Caracò C, Piazzalunga D, Labianca A, Ribero S, Senetta R, Gianatti A, Valeri B, Massi D, Ascierto PA, Santinami M; Italian Melanoma Intergroup (IMI). Mandalà M, et al. Among authors: merelli b. Eur J Cancer. 2020 Sep;137:30-39. doi: 10.1016/j.ejca.2020.07.001. Epub 2020 Jul 30. Eur J Cancer. 2020. PMID: 32739767 Free PMC article.
Corrigendum to "Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicenter study of the Italian Melanoma Intergroup (IMI)" [Eur J Canc 137 (2020). Pages 30-39].
Mandalà M, Galli F, Patuzzo R, Maurichi A, Mocellin S, Rossi CR, Rulli E, Montesco M, Quaglino P, Caliendo V, De Giorgi V, Merelli B, Caracò C, Piazzalunga D, Labianca A, Ribero S, Senetta R, Gianatti A, Valeri B, Massi D, Ascierto PA, Santinami M; Italian Melanoma Intergroup (IMI). Mandalà M, et al. Among authors: merelli b. Eur J Cancer. 2020 Nov;139:204-205. doi: 10.1016/j.ejca.2020.09.002. Epub 2020 Sep 23. Eur J Cancer. 2020. PMID: 32980191 Free PMC article. No abstract available.
61 results